These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 27108602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study.
    Cao W, Li H, Zhang J, Li D, Acheampong DO, Chen Z, Wang M.
    Protein Expr Purif; 2013 Aug; 90(2):55-66. PubMed ID: 23680780
    [Abstract] [Full Text] [Related]

  • 4. Screening and anti-angiogenesis activity of Chiloscyllium plagiosum anti-human VEGFR2 single-domain antibody.
    Guo Y, Wang R, Wang Y, Zheng F, Chen J, Lyu Z, Yuan C, Liu L, Jiang X.
    Clin Exp Immunol; 2024 Oct 16; 218(2):177-187. PubMed ID: 39028612
    [Abstract] [Full Text] [Related]

  • 5. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
    Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S.
    Mol Immunol; 2012 Feb 16; 50(1-2):35-41. PubMed ID: 22208996
    [Abstract] [Full Text] [Related]

  • 6. Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies.
    Karami E, Naderi S, Roshan R, Behdani M, Kazemi-Lomedasht F.
    Cancer Chemother Pharmacol; 2022 Feb 16; 89(2):165-172. PubMed ID: 34988654
    [Abstract] [Full Text] [Related]

  • 7. Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.
    Arezumand R, Mahdian R, Zeinali S, Hassanzadeh-Ghassabeh G, Mansouri K, Khanahmad H, Namvar-Asl N, Rahimi H, Behdani M, Cohan RA, Eavazalipour M, Ramazani A, Muyldermans S.
    Mol Immunol; 2016 Oct 16; 78():183-192. PubMed ID: 27648860
    [Abstract] [Full Text] [Related]

  • 8. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
    Nikooharf A, Arezumand R, Mansouri K, Khoshi AH, Namdar Ahmadabad H.
    Mol Biotechnol; 2020 Dec 16; 62(11-12):580-588. PubMed ID: 32975735
    [Abstract] [Full Text] [Related]

  • 9. VEGFR2 Mimicking Peptide Inhibits the Proliferation of Human Umbilical Vein Endothelial Cells (Huvecs) by Blocking VEGF.
    Ghasemali S, Barzegar A, Farajnia S, Rahmati M, Negahdari B, Etemadi A, Nazari A.
    Anticancer Agents Med Chem; 2023 Dec 16; 23(14):1678-1688. PubMed ID: 37194933
    [Abstract] [Full Text] [Related]

  • 10. Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell.
    Qasemi M, Behdani M, Shokrgozar MA, Molla-Kazemiha V, Mohseni-Kuchesfahani H, Habibi-Anbouhi M.
    Protein Expr Purif; 2016 Jul 16; 123():19-25. PubMed ID: 26996993
    [Abstract] [Full Text] [Related]

  • 11. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
    Farajpour Z, Rahbarizadeh F, Kazemi B, Ahmadvand D.
    Biochem Biophys Res Commun; 2014 Mar 28; 446(1):132-6. PubMed ID: 24569074
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
    Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-Anbouhi M, Abolhassani M, Arezumand R, Shahbazzadeh D, Mirzahoseini H.
    Mol Immunol; 2015 May 28; 65(1):58-67. PubMed ID: 25645505
    [Abstract] [Full Text] [Related]

  • 14. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.
    Li H, Cao W, Chen Z, Acheampong DO, Jin H, Li D, Zhang J, Wang M.
    Biomed Pharmacother; 2013 Sep 28; 67(7):599-606. PubMed ID: 23906761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
    Ahadi M, Ghasemian H, Behdani M, Kazemi-Lomedasht F.
    J Immunotoxicol; 2019 Dec 28; 16(1):34-42. PubMed ID: 30409071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.